Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and raised the price target from $450 to $459 on ...

Vertex Pharmaceuticals reports first-quarter financial results after the market close on Monday. Here's a look at the key highlights from the period.

Vertex said its profit fell due to higher operating expenses and a $379 million intangible asset impairment charge associated with treatment for Type 1 diabetes patients, which the company said in ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company ...

Discover Vertex Pharmaceuticals' Q1 2025 earnings insights, with 3% revenue growth, key product launches like JOURNAVX & ALYFTREK, & raised ...

Vertex Pharmaceuticals (NASDAQ:VRTX) missed on the top and bottom lines in its Q1 financial results and also raised the low ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their ...

Vertex Pharmaceuticals (NASDAQ:VRTX) will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Vertex ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $509.47, moving +1.19% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0 ...

In recent trading, shares of Vertex Pharmaceuticals, Inc. (Symbol: VRTX) have crossed above the average analyst 12-month target price of $509.33, changing hands for $509.47/share. When a stock ...

Amid the launch of its non-opioid pain med Journavx, Vertex Pharmaceuticals has begun an awareness-raising blitz focused on acute pain management. The new campaign stars former NFL quarterback ...